{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T14:09:12Z","timestamp":1791727752282,"version":"4.3.4"},"reference-count":65,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Osteosarcoma remains a major treatment challenge, especially for patients with recurrent, refractory or metastatic diseases. Adoptive cell therapy (ACT), including CAR-T cells, TCR engineered T cells, CAR-NK cells and macrophage based cell therapy, provides a promising strategy for redirecting immune effector cells to fight osteosarcoma. However, clinical translation has been limited by antigen heterogeneity, on-target\/off-tumor toxicity, insufficient tumor trafficking, poor persistence, functional exhaustion, and the immunosuppressive tumor microenvironment. This mini review discusses emerging innovations designed to overcome these safety and efficacy barriers. First, engineering strategies such as multi-antigen recognition, logic-gated CAR systems, suicide switches, transient CAR expression, armored cytokine circuits, checkpoint-resistant designs, and chemokine receptor modification may improve precision, controllability, and durability. Second, vaccination approaches may serve as programmable amplifiers of ACT by promoting\n                    <jats:italic>in vivo<\/jats:italic>\n                    expansion, immune memory, antigen spreading, and local inflammatory priming. Third, tumor microenvironment remodeling through stromal modulation, vascular normalization, myeloid reprogramming, checkpoint blockade, and metabolic intervention may convert osteosarcoma into a more permissive niche for cellular therapy. Collectively, next-generation ACT for osteosarcoma will likely require modular, biomarker-guided combinations that integrate cellular engineering, vaccine-based boosting, and microenvironmental remodeling to achieve safer and more durable antitumor responses.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2026.1865742","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T05:38:25Z","timestamp":1780637905000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Reprogramming adoptive cell therapy for osteosarcoma: engineering, vaccination, and tumor microenvironment remodeling"],"prefix":"10.3389","volume":"17","author":[{"given":"Shiguo","family":"Zuo","sequence":"first","affiliation":[{"name":"Department of Spine Surgery, Qianxinan Autonomous Prefecture Hospital of Traditional Chinese Medicine","place":["Xingyi, Guizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Psychology, Xijing Hospital 986 Hospital, Fourth Military Medical University","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiying","family":"Hou","sequence":"additional","affiliation":[{"name":"Department of Spine Surgery, Qianxinan Autonomous Prefecture Hospital of Traditional Chinese Medicine","place":["Xingyi, Guizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilong","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Spine Surgery, Qianxinan Autonomous Prefecture Hospital of Traditional Chinese Medicine","place":["Xingyi, Guizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanliang","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Spine Surgery, Qianxinan Autonomous Prefecture Hospital of Traditional Chinese Medicine","place":["Xingyi, Guizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yisheng","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Qianxinan Autonomous Prefecture Hospital of Traditional Chinese Medicine","place":["Xingyi, Guizhou, China"]},{"name":"Department of Orthopedics, Guangdong Provincial Hospital of TraditionalChinese Medicine","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24121","article-title":"Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program","volume":"115","author":"Mirabello","year":"2009","journal-title":"Cancer"},{"key":"B2","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4419-0284-9_1","article-title":"The epidemiology of osteosarcoma","volume-title":"Springer US","author":"Ottaviani","year":"2009"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3838","article-title":"Translational biology of osteosarcoma","volume":"14","author":"Kansara","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.59.4895","article-title":"Osteosarcoma: current treatment and a collaborative pathway to success","volume":"33","author":"Isakoff","year":"2015","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2002.20.12.2910","article-title":"Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols","volume":"17","author":"Ferrari","year":"2004","journal-title":"Hum Cell"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30624-1","article-title":"Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial","volume":"18","author":"Tawbi","year":"2017","journal-title":"Lancet Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-062315-120245","article-title":"CAR T cell therapy for solid tumors","volume":"68","author":"Newick","year":"2017","journal-title":"Annu Rev Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.0225","article-title":"Human epidermal growth factor receptor 2 (HER2) -specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma","volume":"33","author":"Ahmed","year":"2015","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-024-00749-6","article-title":"Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial","volume":"5","author":"Hegde","year":"2024","journal-title":"Nat Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1394","article-title":"Surface expression of the immunotherapeutic target GD2 in osteosarcoma depends on cell confluency","volume":"4","author":"Wiebel","year":"2021","journal-title":"Cancer Rep (Hoboken)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-3298","article-title":"Redirecting B7-H3.CAR T cells to chemokines expressed in osteosarcoma enhances homing and antitumor activity in preclinical models","volume":"30","author":"Talbot","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1186\/s12885-022-10229-8","article-title":"B7-H3 targeted CAR-T cells show highly efficient anti-tumor function against osteosarcoma both in vitro and in vivo","volume":"22","author":"Zhang","year":"2022","journal-title":"BMC Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0432","article-title":"CAR T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors","volume":"25","author":"Majzner","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor antigen escape from CAR T-cell therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov"},{"key":"B16","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1158\/2326-6066.CIR-15-0231","article-title":"T cells expressing CD19\/CD20 bispecific chimeric antigen receptors prevent antigen escape by Malignant B cells","volume":"4","author":"Zah","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.01.011","article-title":"Precision tumor recognition by T cells with combinatorial antigen-sensing circuits","volume":"164","author":"Roybal","year":"2016","journal-title":"Cell"},{"key":"B18","doi-asserted-by":"publisher","first-page":"215ra172","DOI":"10.1126\/scitranslmed.3006597","article-title":"PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses","volume":"5","author":"Fedorov","year":"2013","journal-title":"Sci Transl Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-11-4564","article-title":"An inducible caspase 9 safety switch for T-cell therapy","volume":"105","author":"Straathof","year":"2005","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1106152","article-title":"Inducible apoptosis as a safety switch for adoptive cell therapy","volume":"365","author":"Di Stasi","year":"2011","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0170","article-title":"Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid Malignancies","volume":"2","author":"Beatty","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.4086","article-title":"IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor","volume":"36","author":"Adachi","year":"2018","journal-title":"Nat Biotechnol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"10541","DOI":"10.1038\/s41598-017-10940-8","article-title":"Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment","volume":"7","author":"Yeku","year":"2017","journal-title":"Sci Rep"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1610544113","article-title":"Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells","volume":"113","author":"Hurton","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"B26","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/s41598-017-00462-8","article-title":"CRISPR\/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells","volume":"7","author":"Rupp","year":"2017","journal-title":"Sci Rep"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.05.003","article-title":"Dominant-negative TGF-\u03b2 receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication","volume":"26","author":"Kloss","year":"2018","journal-title":"Mol Ther"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1126\/science.aay5967","article-title":"An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors","volume":"367","author":"Reinhard","year":"2020","journal-title":"Science"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02612-0","article-title":"CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial","volume":"29","author":"Mackensen","year":"2023","journal-title":"Nat Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/nm.1882","article-title":"Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma","volume":"14","author":"Pule","year":"2008","journal-title":"Nat Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-354449","article-title":"Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma","volume":"118","author":"Louis","year":"2011","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-506741","article-title":"Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell Malignancies relapsed after allogeneic stem cell transplant: a phase 1 study","volume":"122","author":"Cruz","year":"2013","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2138","article-title":"Vaccination targeting native receptors to enhance the function and proliferation of chimeric antigen receptor (CAR)-modified T cells","volume":"23","author":"Tanaka","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1860","article-title":"Dual-specific chimeric antigen receptor T cells and an indirect vaccine eradicate a variety of large solid tumors in an immunocompetent, self-antigen setting","volume":"23","author":"Slaney","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-012-0795-1","article-title":"Lack of T-cell responses following autologous tumour lysate pulsed dendritic cell vaccination, in patients with relapsed osteosarcoma","volume":"14","author":"Himoudi","year":"2012","journal-title":"Clin Transl Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1080\/07357900701508918","article-title":"Allogeneic tumor vaccine produced by electrofusion between osteosarcoma cell line and dendritic cells in the induction of antitumor immunity","volume":"25","author":"Yu","year":"2007","journal-title":"Cancer Invest"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.10.019","article-title":"STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors","volume":"41","author":"Deng","year":"2014","journal-title":"Immunity"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3390\/cells9040976","article-title":"The osteosarcoma microenvironment: a complex but targetable ecosystem","volume":"9","author":"Corre","year":"2020","journal-title":"Cells"},{"key":"B40","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41413-023-00246-z","article-title":"Managing the immune microenvironment of osteosarcoma: the outlook for osteosarcoma treatment","volume":"11","author":"Tian","year":"2023","journal-title":"Bone Res"},{"key":"B41","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s13046-020-01685-w","article-title":"The role of extracelluar matrix in osteosarcoma progression and metastasis","volume":"39","author":"Cui","year":"2020","journal-title":"J Exp Clin Cancer Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.871076","article-title":"Effects of microenvironment in osteosarcoma on chemoresistance and the promise of immunotherapy as an osteosarcoma therapeutic modality","volume":"13","author":"Yu","year":"2022","journal-title":"Front Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3181ee6675","article-title":"Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b","volume":"33","author":"Craddock","year":"2010","journal-title":"J Immunother"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.12.7516","article-title":"Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor","volume":"174","author":"Lugade","year":"2005","journal-title":"J Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.3653","article-title":"Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers","volume":"31","author":"Jain","year":"2013","journal-title":"J Clin Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3833","article-title":"Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes","volume":"21","author":"Caruana","year":"2015","journal-title":"Nat Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.586580","article-title":"Macrophages in osteosarcoma immune microenvironment: implications for immunotherapy","volume":"10","author":"Luo","year":"2020","journal-title":"Front Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-00490-y","article-title":"Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity","volume":"21","author":"Veglia","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-1816","article-title":"Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy","volume":"74","author":"Mok","year":"2014","journal-title":"Cancer Res"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.4282","article-title":"CD47 blockade inhibits tumor progression human osteosarcoma in xenograft models","volume":"6","author":"Xu","year":"2015","journal-title":"Oncotarget"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/nature20554","article-title":"Overcoming resistance to checkpoint blockade therapy by targeting PI3K\u03b3 in myeloid cells","volume":"539","author":"De Henau","year":"2016","journal-title":"Nature"},{"key":"B52","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"B53","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s40425-018-0360-8","article-title":"Targeting adenosine for cancer immunotherapy","volume":"6","author":"Leone","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B54","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.omto.2022.03.009","article-title":"CAR T cell therapy and the tumor microenvironment: Current challenges and opportunities","volume":"25","author":"Kankeu Fonkoua","year":"2022","journal-title":"Mol Ther Oncolytics"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15204970","article-title":"Osteosarcoma multi-omics landscape and subtypes","volume":"15","author":"Tang","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B57","doi-asserted-by":"publisher","first-page":"6322","DOI":"10.1038\/s41467-020-20059-6","article-title":"Single-cell RNA landscape of intratumoral heterogeneity and immunosuppressive microenvironment in advanced osteosarcoma","volume":"11","author":"Zhou","year":"2020","journal-title":"Nat Commun"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102697","article-title":"Tumor-informed deep sequencing of ctDNA detects minimal residual disease and predicts relapse in osteosarcoma","volume":"73","author":"Fu","year":"2024","journal-title":"EClinicalMedicine"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20230903","article-title":"CAR-T cell manufacturing: Major process parameters and next-generation strategies","volume":"221","author":"Ayala Ceja","year":"2024","journal-title":"J Exp Med"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_397912","article-title":"High cost of chimeric antigen receptor T-cells: Challenges and solutions","volume":"43","author":"Cliff","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.732135","article-title":"Current perspectives on \u2018off-the-shelf\u2019 allogeneic NK and CAR-NK cell therapies","volume":"12","author":"Heipertz","year":"2021","journal-title":"Front Immunol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117252","article-title":"Antigen escape in CAR-T cell therapy: Mechanisms and overcoming strategies","volume":"178","author":"Lin","year":"2024","journal-title":"BioMed Pharmacother"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008450","article-title":"Dynamic monitoring of circulating tumor DNA reveals outcomes and genomic alterations in patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy","volume":"12","author":"Zou","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02262","article-title":"Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL","volume":"39","author":"Shah","year":"2021","journal-title":"J Clin Oncol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1056\/NEJMra1510062","article-title":"Master protocols to study multiple therapies, multiple diseases, or both","volume":"377","author":"Woodcock","year":"2017","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1865742\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T05:38:27Z","timestamp":1780637907000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1865742\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":65,"alternative-id":["10.3389\/fimmu.2026.1865742"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1865742","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,5]]},"article-number":"1865742"}}